Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-09
2006-05-09
Jiang, Shaojia Anna (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S311000, C514S305000, C514S708000, C514S306000, C514S307000, C514S299000
Reexamination Certificate
active
07041677
ABSTRACT:
The present invention described the administration of halogenated flosequinan derivatives and the enantiomers of halogenated flosequinan derivatives for the treatment of sexual dysfunction (in males and females) and for the treatment of cardiovascular disease.
REFERENCES:
patent: 1897423 (1933-02-01), Ferri
patent: 2584166 (1952-02-01), Stevenson et al.
patent: 2696209 (1954-12-01), Varaney
patent: 3373746 (1968-03-01), White et al.
patent: 4311707 (1982-01-01), Birnbaum et al.
patent: 4478822 (1984-10-01), Haslam et al.
patent: 4552891 (1985-11-01), Ho et al.
patent: 4610868 (1986-09-01), Fountain et al.
patent: 4640912 (1987-02-01), Hausman
patent: 4746508 (1988-05-01), Carey et al.
patent: 4801587 (1989-01-01), Voss et al.
patent: 5011931 (1991-04-01), MacLean et al.
patent: 5079264 (1992-01-01), MacLean et al.
patent: 5393773 (1995-02-01), Craig et al.
patent: 5447912 (1995-09-01), Gerstenberg et al.
patent: 5474535 (1995-12-01), Place et al.
patent: 5554639 (1996-09-01), Craig et al.
patent: 5801161 (1998-09-01), Merkus
patent: 5864037 (1999-01-01), Chasin et al.
patent: 5869479 (1999-02-01), Kreutner et al.
patent: 6110489 (2000-08-01), Cutler
patent: 6132753 (2000-10-01), Cutler
patent: 6132757 (2000-10-01), Cutler
patent: 6194433 (2001-02-01), Cutler
patent: 6258373 (2001-07-01), Cutler
patent: 6451813 (2002-09-01), Cutler et al.
patent: 0357581 (1998-09-01), None
patent: WO 99/56666 (1999-11-01), None
Baehr et al. “Isolation and characterization of cGMP phosphodiesterase from bovine rod outer segments”J. Biol. Chem. 254:11669-11677 (1979).
Cold, C.J. and Taylor, J.R., “The Prepuce,”British Journal of Urology, 83, Suppl. 1:34-44 (1999).
Cortijo et al., “Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus,”J. Pharmacol. 108:562-568 (1993).
Hidaka and Agano, “Human blood platelet 3′:5′ cyclic nucleotide phosphodiesterase. Isolation of low-Km and high-Km phosphodiesterase,”Biochem. Biophys. Acta429:485-497 (1976).
Lue et al., “Physiology of erection and pharmacological management of impotence,”J. Urol. 37:829-836 (1987).
Morita et al., “Synthesis and Absolute Configuration of the Enantiomers of 7-Fluoro-1-methyl-3-(methylsulfinyl)-4(1H)-quinolinone (Flosequinan),”Chem. Pharm. Bull., 42(10):2157-2160 (1994).
Park et al., “Vasculogenic female sexual dysfunction: The hemodynamic basis for vaginal engorgement insufficiency and clitoral erectile insufficiency,”Int. J. Impotence Res. 9:27-37 (1997).
Porst et al., “Relevance of dynamic cavernosography to the diagnosis of venous incompetence in erectile dysfunction,”J. Urol. 137:1163-1167 (1987).
Jiang Shaojia Anna
Medlen & Carroll LLP
R.T. Alamo Ventures I, LLC
LandOfFree
Use of monochloroflosequinan in the treatment of sexual... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of monochloroflosequinan in the treatment of sexual..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of monochloroflosequinan in the treatment of sexual... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3638014